Photo credit: www.investing.com

Gilead Sciences and U.S. Government Reach Settlement Over HIV Drug Patent Battle

Gilead Sciences has successfully resolved a billion-dollar patent lawsuit with the U.S. government regarding its HIV prevention medications, Truvada and Descovy, as detailed in a recent Delaware federal court filing.

This settlement follows a favorable ruling for Gilead in a 2023 jury trial where they defended against claims of patent infringement brought by the government.

Deborah Telman, Gilead’s General Counsel, expressed relief over the agreement, stating it allows the company to concentrate its efforts on its core mission of developing innovative treatments for serious illnesses.

Representatives from the U.S. Department of Health and Human Services and the Centers for Disease Control and Prevention (CDC) did not provide immediate comments regarding the terms or implications of the settlement.

Gilead, based in Foster City, California, collaborated with the CDC during the mid-2000s to evaluate the potential of Truvada not only as a treatment but also as a preventative measure against HIV transmission. The government alleged that Gilead had not adequately compensated the CDC for its pivotal role in demonstrating Truvada’s efficacy in preventing HIV infections.

The government’s lawsuit accused Gilead of overstating its contributions to the development of the HIV-prevention regimen known as pre-exposure prophylaxis (PrEP), while disregarding the CDC’s input and failing to negotiate licensing for the CDC’s patented technologies.

In pre-trial documentation, the government asserted it was entitled to claim damages amounting to $691 million related to Truvada and $311 million concerning Descovy. Gilead’s financial performance showed that the company generated over $1.8 billion from U.S. sales of these drugs in 2023 alone.

In a separate legal decision made in 2022, a Washington, D.C. federal court found that the government had violated agreements related to their research collaboration with Gilead by seeking patents without proper notification.

The resolution of this lawsuit marks a significant moment for Gilead as it continues to navigate the complexities of pharmaceutical innovation and intellectual property rights in the healthcare sector.

Source
www.investing.com